Advertisement

MRI-Detectability of Clinically Significant Prostate Cancer Relates to Oncologic Outcomes After Prostatectomy

Published:April 14, 2022DOI:https://doi.org/10.1016/j.clgc.2022.04.001

      Abstract

      Introduction/Background

      Magnetic resonance imaging (MRI) misses a proportion of “clinically significant” prostate cancers (csPC) as defined by histopathology criteria. The aim of this study was to analyze whether long-term oncologic outcomes differ between MRI-detectable and MRI-occult csPC.

      Patients and Methods

      Retrospective analysis of 1449 patients with pre-prostatectomy MRI and csPC on prostatectomy specimens (ie, Grade group ≥2 or extraprostatic spread) between 2001-2006. T2-weighted MRIs were classified according to the Prostate Imaging Reporting and Data System into MRI-occult (categories 1, 2), MRI-equivocal (category 3), and MRI-detectable (categories 4, 5). Cumulative incidence of biochemical recurrence (BCR), metastatic disease, and cancer-specific mortality, estimated with competing risk models. The median follow-up in survivors was 11.0 years (IQR: 8.9-13.1).

      Results

      In 188 (13%) cases, csPC was MRI-occult, 435 (30%) MRIs were equivocal, and 826 (57%) csPC were MRI-detectable. The 15-year cumulative incidence [95% CI] of BCR was 8.3% [2.2, 19.5] for MRI-occult cases, 17.4% [11.1, 24.8] for MRI-equivocal cases, and 43.3% [38.7, 47.8] for MRI-detectable cases (P < .001). The cumulative incidences of metastases were 0.61% [0.06, 3.1], 3.5% [1.5, 6.9], and 19.6% [15.4, 24.2] for MRI-occult, MRI-equivocal, and MRI-detectable cases, respectively (P < .001). There were no deaths from prostate cancer observed in patients with MRI-occult csPC, compared to an estimated 1.9% [0.54, 4.9], and 7.1 % [4.5, 10.6] for patients with MRI-equivocal and MRI-detectable cancer, respectively (P < .001).

      Conclusion

      Oncologic outcomes after prostatectomy for csPC differ between MRI-occult and MRI-detectable lesions. Judging the clinical significance of a negative prostate MRI based on histopathologic surrogates alone might be misleading.

      Microabstract

      Among 1449 patients with pre-prostatectomy MRI and clinically significant prostate cancer on prostatectomy histopathology, MRI-occult cancers (n = 188, 13%) were less likely to recur biochemically (8% vs. 43%, P < .001), metastasize (0.6% vs. 20%, P < .001), or lead to prostate cancer mortality (0% vs. 7%, P < .001) than MRI-detectable cancers (n = 826, 57%). MRI-occult cancers constitute a prognostically distinct subgroup among higher-grade prostate cancers.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Woo S.
        • Suh C.H.
        • Eastham J.A.
        • Zelefsky M.J.
        • Morris M.J.
        • Abida W.
        Comparison of magnetic resonance imaging-stratified clinical pathways and systematic transrectal ultrasound-guided biopsy pathway for the detection of clinically significant prostate cancer: a systematic review and meta-analysis of randomized controlled trials.
        Eur Urol Oncol. 2019; 2: 605-616
        • Johnson D.C.
        • Raman S.S.
        • Mirak S.A.
        • Kwan L.
        • Bajgiran A.M.
        • Hsu W.
        Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging.
        Eur Urol. 2019; 75: 712-720
        • Woo S.
        • Suh C.H.
        • Kim S.Y.
        • Cho J.Y.
        • Kim S.H.
        Diagnostic performance of prostate imaging reporting and data system version 2 for detection of prostate cancer: a systematic review and diagnostic meta-analysis.
        Eur Urol. 2017; 72: 177-188
        • Barkovich E.J.
        • Shankar P.R.
        • Westphalen A.C.
        A Systematic review of the existing prostate imaging reporting and data system version 2 (PI-RADSv2) literature and subset meta-analysis of PI-RADSv2 categories stratified by Gleason scores.
        AJR Am J Roentgenol. 2019; 212: 847-854
        • Grimm P.
        • Billiet I.
        • Bostwick D.
        • Dicker A.P.
        • Frank S.
        • Immerzeel J.
        Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the prostate cancer results study group.
        BJU Int. 2012; 109 (suppl 1): 22-29
        • Kane C.J.
        • Eggener S.E.
        • Shindel A.W.
        • Andriole G.L.
        Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason score 7, international society of urological pathology Gleason group 2-3) and implications for risk stratification: a systematic review.
        Eur Urol Focus. 2017; 3: 487-497
        • Stabile A.
        • Mazzone E.
        • Cirulli G.O.
        • De Cobelli F.
        • Grummet J.
        • Thoeny H.C.
        Association between multiparametric magnetic resonance imaging of the prostate and oncological outcomes after primary treatment for prostate cancer: a systematic review and meta-analysis.
        Eur Urol Oncol. 2021; 4: 519-528
        • Wibmer A.G.
        • Chaim J.
        • Lakhman Y.
        • Lefkowitz R.A.
        • Nincevic J.
        • Nikolovski I.
        Oncologic outcomes after localized prostate cancer treatment: associations with pretreatment prostate magnetic resonance imaging findings.
        J Urol. 2021; 205: 1055-1062
        • Weinreb J.C.
        • Barentsz J.O.
        • Choyke P.L.
        • Cornud F.
        • Haider M.A.
        • Macura K.J.
        PI-RADS prostate imaging - reporting and data system: 2015, version 2.
        Eur Urol. 2016; 69: 16-40
        • Jambor I.
        • Falagario U.
        • Ratnani P.
        • Perez I.M.
        • Demir K.
        • Merisaari H.
        Prediction of biochemical recurrence in prostate cancer patients who underwent prostatectomy using routine clinical prostate multiparametric MRI and decipher genomic score.
        J Magn Reson Imaging JMRI. 2020; 51: 1075-1085
        • Capogrosso P.
        • Vertosick E.A.
        • Benfante N.E.
        • Sjoberg D.D.
        • Vickers A.J.
        • Eastham J.A.
        Can we improve the preoperative prediction of prostate cancer recurrence with multiparametric MRI?.
        Clin Ggenitourin Cancer. 2019; 17 (e745-e50)
        • Turchan W.T.
        • Kauffmann G.
        • Patel P.
        • Oto A.
        • Liauw S.L.
        PI-RADS score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy.
        Urol Oncol. 2020; 38: 600
        • Carlsson S.V.
        • Eastham J.A.
        Re: use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study.
        Eur Urol. 2019; 76: 534-535
        • Rider J.
        • Sandin F.
        • Andren O.
        • Wiklund P.
        • Hugosson J.
        • Stattin P.
        Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
        Eur Urol. 2013; 63: 88-96
        • Rasul R.
        • Golden A.
        • Feuerstein M.A.
        Prostate cancer risk group is associated with other-cause mortality in men with localized prostate cancer.
        Can Urol Assoc J. 2020; 14 (E507-e13)
        • Pierre V.D.
        • Pinsky P.F.
        • Miller E.
        • Parnes H.
        Other- and all-cause mortality among men diagnosed with prostate cancer in the PLCO trial.
        J Urol. 2020; (101097ju0000000000001531)
        • Holmberg L.
        • Bill Axelson A.
        • Steineck G.
        • Garmo H.
        • Palmgren J.
        • Johansson E.
        Results from the scandinavian prostate cancer group trial number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.
        J Natl Cancer Inst Monogr. 2012; 2012: 230-233
        • Wilt T.J.
        • Brawer M.K.
        • Jones K.M.
        • Barry M.J.
        • Aronson W.J.
        • Fox S.
        Radical prostatectomy versus observation for localized prostate cancer.
        N Engl J Med. 2012; 367: 203-213
        • Tan C.H.
        • Hobbs B.P.
        • Wei W.
        • Kundra V.
        Dynamic contrast-enhanced MRI for the detection of prostate cancer: meta-analysis.
        AJR Am J Roentgenol. 2015; 204: W439-W448
        • Akin O.
        • Riedl C.C.
        • Ishill N.M.
        • Moskowitz C.S.
        • Zhang J.
        • Hricak H.
        Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer.
        Eur Radiol. 2010; 20: 995-1002
        • Wibmer A.
        • Vargas H.A.
        • Donahue T.F.
        • Zheng J.
        • Moskowitz C.
        • Eastham J.
        Diagnosis of extracapsular extension of prostate cancer on prostate MRI: impact of second-opinion readings by subspecialized genitourinary oncologic radiologists.
        AJR Am J Roentgenol. 2015; 205: W73-W78
        • Brimo F.
        • Schultz L.
        • Epstein J.I.
        The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy.
        J Urol. 2010; 184: 126-130
        • Barqawi A.B.
        • Turcanu R.
        • Gamito E.J.
        • Lucia S.M.
        • O'Donnell C.I.
        • Crawford E.D.
        The value of second-opinion pathology diagnoses on prostate biopsies from patients referred for management of prostate cancer.
        Int J Clin Exp Pathol. 2011; 4: 468-475
        • Cohen M.S.
        • Hanley R.S.
        • Kurteva T.
        • Ruthazer R.
        • Silverman M.L.
        • Sorcini A.
        Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey clinic medical center experience and an international meta-analysis.
        Eur Urol. 2008; 54: 371-381
        • Wibmer A.G.
        • Nikolovski I.
        • Chaim J.
        • et al.
        Local Extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: Associations with Long-term Oncologic Outcomes.
        Radiology. 2022; 302: 595-602